Related Experiment Video

Updated: Jun 11, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Hyperbilirubinemia in healthy neonates with glucose-6-phosphate dehydrogenase deficiency

Yi-Hao Weng1, Yi-Hung Chou, Rey-In Lien

  • 1Department of Pediatrics, Division of Neonatology, Chang Gung Children's Hospital, 5 Fu-Shin Street, Kueishan, Taoyuan, Taiwan.

Early Human Development
|March 29, 2003
PubMed

Insights

Glucose-6-phosphate dehydrogenase (G6PD) deficiency increases the risk of neonatal hyperbilirubinemia in newborns. Lower G6PD enzyme activity in males with hyperbilirubinemia suggests a significant association.

Area of Science:

  • Neonatology
  • Medical Genetics
  • Biochemistry

Background:

  • Neonatal hyperbilirubinemia is a common condition.
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited enzyme disorder.
  • The association between G6PD deficiency and neonatal hyperbilirubinemia requires further investigation.

Purpose of the Study:

  • To assess the association between G6PD deficiency and neonatal hyperbilirubinemia.
  • To compare the incidence of hyperbilirubinemia in G6PD-deficient versus G6PD-normal newborns.
  • To investigate the relationship between G6PD enzyme activity and hyperbilirubinemia in G6PD-deficient neonates.

Main Methods:

  • A cohort study was conducted involving 42,110 inborn infants.
  • G6PD deficiency was diagnosed using a quantitative enzyme assay.
  • Neonatal hyperbilirubinemia was defined as serum total bilirubin >/= 15 mg/dl.

Main Results:

  • G6PD deficiency was identified in 3.54% of males and 1.57% of females.
  • Hyperbilirubinemia incidence was significantly higher in G6PD-deficient males (11.36%) and females (7.06%) compared to G6PD-normal infants.
  • Lower G6PD enzyme activity was significantly associated with hyperbilirubinemia in G6PD-deficient males, but not females.

Conclusions:

  • G6PD-deficient neonates face an elevated risk of hyperbilirubinemia, even without hemolytic agents.
  • Lower G6PD enzyme activity is linked to neonatal hyperbilirubinemia in G6PD-deficient males.
  • G6PD deficiency is a significant risk factor for neonatal hyperbilirubinemia.

More Related Videos

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina07:04

Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina

Published on: March 14, 2025

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...